- Raised $30M funding round, Mar 2018
- Raised $20M funding round, Jun 2013
About
Medial EarlySign’s AI-driven machine learning solutions empower healthcare stakeholders to keep patients healthier for extended periods. The company’s advanced models derive actionable clinical insights from massive datasets, helping improve patient outcomes, optimize diagnostics, and enhance medication management. Medial EarlySign's purpose-built development environment ensures precision decision-making, supported by peer-reviewed studies published by leading healthcare organizations worldwide.
EarlySign helps clients identify people at high risk for conditions such as non-small cell lung cancer (NSCLC), lower GI disorders and cancers, prediabetic progression to diabetes, downstream diabetic complications, risk for flu and its complications, chronic kidney disease (CKD), COVID-19, and more.
The company was named a cool vendor in "Cool Vendors in AI for Healthcare, 2017" by the Gartner Research Group and was a winner of the CMS AI Health Outcomes Challenge.
Funding history · 2 rounds · $50.0M total
Q&A
- What is Medial EarlySign's primary focus?
- Medial EarlySign specializes in AI-driven machine learning solutions for the early detection of life-threatening conditions, aiming to improve patient outcomes and optimize diagnostics.
- What is the current status of Medial EarlySign?
- Medial EarlySign is currently inactive, having ceased operations in October 2025.
- When was Medial EarlySign founded?
- Medial EarlySign was founded in January 2009.
- How much funding has Medial EarlySign raised to date?
- Medial EarlySign has raised a total of $50,000,000 USD.
- Which investors participated in Medial EarlySign's March 2018 funding round?
- In March 2018, Medial EarlySign raised $30,000,000 USD with participation from aMoon Fund.
- Which investors participated in Medial EarlySign's June 2013 funding round?
- In June 2013, Medial EarlySign raised $20,000,000 USD with participation from.
- What is Medial EarlySign's employee count?
- Medial EarlySign has an employee count in the 11-50 range.
- What types of conditions does Medial EarlySign's technology help identify?
- Medial EarlySign's technology helps identify people at high risk for conditions such as non-small cell lung cancer (NSCLC), lower GI disorders and cancers, prediabetic progression to diabetes, and chronic kidney disease (CKD).
Team · 4
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/7959149 | |
| facebook.com/MedialEarlySign | |
| YouTube | youtube.com/channel/UChC6yPWf4P6yXGC-MqoupEw |
Identifiers & details
| Former names | Medial Research, Medial CS |
|---|---|
| Founded | 2009-1 |
| Employees (exact) | 12 |
| Offices | Aurora |
| Status reason | Non Active, Oct 2025 ceased to operate |